Dulucq, Stephanie <br/><br/>
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.  [electronic resource] 

 -  Annals of hematology  May 2019 
 - 1159-1168 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-0584 
<br/><br/><label>Standard No.: </label>10.1007/s00277-019-03633-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Disease-Free Survival<br/>Female<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Imatinib Mesylate--administration & dosage<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>RNA, Messenger--genetics<br/>RNA, Neoplasm--genetics<br/>Survival Rate